wound model is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
== Disease cycle == D. dadantii is able to infect the fleshy, succulent plant parts, such as tubers, rhizomes, stems and leaves, causing localized symptoms. As discussed in the symptoms section, it is also capable of infecting the xylem, resulting in a systemic infection that causes wilting. D. dadantii typically originates from infected insects, vegetables or host plant residues. However, the bacteria are also able to survive in soils and other plants without infection. The ability of D. dadantii to live in the soil as a plant pathogen is regulated by virulence genes in response to environmental factors that control whether the bacterium is saprophytic or pathogenic. When D. dadantii is virulent it enters primarily through hydathodes and wounds, with the assistance of jasmonates, where the bacteria rapidly breakdown the parenchymatous tissues with the use of pectic enzymes. D. dadantii produces many pectinases that are responsible for disassembly of the plant cell wall. After the cell wall is degraded, and the contents of the cell are accessed, D. dadantii catabolizes glucose by a fermentation pathway. After the plant has been accessed, colonization is a complicated process that requires many additional factors for successful infection. These factors include: "cellulases, iron assimilation, a Hrp type III secretion system, exopolysaccharides, motility, and proteins involved in resistance against plant defense mechanisms". The plant attempts to resist the infection with different defense mechanisms and D.
On November 28, 2025, The Washington Post published an article alleging Hegseth had given a spoken order to kill the survivors of a September 2, 2025, strike led by SEAL Team 6 on a boat suspected of carrying drugs in the Caribbean Sea. The operation was overseen by Admiral Frank M. "Mitch" Bradley, from Fort Bragg in North Carolina. Bradley described the survivors as legitimate targets, as they could theoretically have contacted other traffickers to rescue them and their cargo, and subsequently ordered the second strike to complete Hegseth's order that everyone must be killed. Hegseth's explanation for the strike has shifted over time. The Office of Legal Counsel eventually argued that the strike was legal because its goal was to destroy the boat, not to kill the crew, reflecting a secret legal memo endorsing such strikes; the memo has been "fiercely criticized" by legal experts. The strike was the first in a series of strikes against suspected drug traffickers. Hegseth's alleged orders were characterized by several legal experts as murder and a war crime. The alleged orders were condemned by members of congress, including Representative Seth Moulton, who said "Mark my words: It may take some time, but Americans will be prosecuted for this, either as a war crime or outright murder." Both Senators Tim Kaine and Mark Kelly described the alleged orders as a war crime.
==== Earl G. Graves School of Business and Management ==== The Earl G. Graves School of Business and Management (GSBM) is named in honor of alumnus Earl G. Graves, Sr. and is housed in the Graves School of Business and Management building, which was opened for the Fall Semester 2015 at the western edge of the campus. It contains classrooms, laboratories, and office buildings with rooms for hospitality management students to operate. The GSBM offers Bachelor of Science, Master of Science, Master of Business Administration, and PhD degree programs. These programs are accredited by The Association to Advance Collegiate Schools of Business (AACSB).
==== Chemically reactive agents ==== Agents such as hydrogen peroxide, elemental chlorine, hypochlorous acid (chlorine water), bromine, bromine water, iodine, nitric and oxidising acids, and ozone react with sensitive moieties such as sulfide/thiol, activated aromatic rings (phenylalanine) in effect damage the protein and render it useless.
Sources: en.wikipedia.org
Propranolol is indicated for the treatment of hypertension (high blood pressure). angina pectoris, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, and pheochromocytoma (catecholamine-secreting tumors). Propranolol is also indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. Beta blockers were once a first-line treatment for hypertension in the United Kingdom. They were downgraded to fourth-line in 2006 because they do not perform as well as other drugs, particularly in the elderly, and there is increasing evidence that the most common beta blockers at usual doses carry an unacceptable risk of provoking type 2 diabetes. Propranolol is not recommended for the treatment of high blood pressure by the Eighth Joint National Committee (JNC 8) because a higher rate of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke compared to an angiotensin receptor blocker was noted in one study.
== Side effects == While botulinum toxin is generally considered safe in a clinical setting, serious side effects from its use can occur. Most commonly, botulinum toxin can be injected into the wrong muscle group or with time spread from the injection site, causing temporary paralysis of unintended muscles. In at least three cases temporary diplopia was reported due to subcutaneous injections for cosmetic purposes. Side effects from cosmetic use generally result from unintended paralysis of facial muscles. These include partial facial paralysis, muscle weakness, and trouble swallowing. Side effects are not limited to direct paralysis, however, and can also include headaches, flu-like symptoms, and allergic reactions. Just as cosmetic treatments only last a number of months, paralysis side effects can have the same durations. At least in some cases, these effects are reported to dissipate in the weeks after treatment. Bruising at the site of injection is not a side effect of the toxin, but rather of the mode of administration, and is reported as preventable if the clinician applies pressure to the injection site; when it occurs, it is reported in specific cases to last 7–11 days. When injecting the masseter muscle of the jaw, loss of muscle function can result in a loss or reduction of power to chew solid foods. With continued high doses, the muscles can atrophy or lose strength; research has shown that those muscles rebuild after a break from Botox.
== Statistics == The following table of executions was compiled by Amnesty International from several sources, including statistics supplied by the Ministry of Home Affairs in January 2001 and government figures reported to Agence France-Presse in September 2003. Numbers in curly brackets are the number of foreign citizens executed, according to information disclosed by the Ministry of Home Affairs.
== Arts and entertainment == Laurel and Hardy, a comedy double act during the early Classical Hollywood era of American cinema "Little Hide", 1998 single by Snow Patrol Lovehammers, a Chicago-based band Love Hina, a 1998 popular manga (and anime) series by author Ken Akamatsu The Lurking Horror, an interactive fiction game released in 1987
== Chemistry == In terms of chemical structure, methocinnamox is a cinnamoylamidomorphinan and is closely related to clocinnamox and methoclocinnamox. It was derived via structural modification of buprenorphine.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.